RxDoctor Payments Data

Constance Bradford

Family · Monticello, MSNPI 1003960907

Payments from drug & device makers

$562in general payments, 2019–2025

Across 24 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$158
  • AbbVie$99
  • Novo Nordisk$86
  • Johnson & Johnson$58
  • Axsome Therapeutics, Inc.$36
  • Abbott$35
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562 in reported general payments places this provider in the 55th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$61,511
Medicare patients
109
Services billed
1,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$169,501
LinzessLinaclotide132$94,535
MounjaroTirzepatide49$66,116
JardianceEmpagliflozin56$59,947
JanuviaSitagliptin Phosphate54$39,012
TrulicityDulaglutide36$37,885
EliquisApixaban34$34,630
TradjentaLinagliptin41$33,035
Tresiba Flextouch U-200Insulin Degludec23$29,075
Tresiba Flextouch U-100Insulin Degludec16$18,855
EntrestoSacubitril/Valsartan17$17,505
FarxigaDapagliflozin Propanediol18$11,956
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$10,505
XareltoRivaroxaban18$9,623
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$9,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$86$169,501130 claims
Lilly USA, LLCMounjaro, Trulicity$31$104,00185 claims
AbbVieLinzess$99$94,535132 claims
Boehringer IngelheimJardiance, Tradjenta$24$92,98197 claims
PfizerEliquis$20$34,63034 claims
Johnson & JohnsonXarelto$58$9,62318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,007 family providers in Mississippi.

Other family in Monticello

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →